Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs SEC filings (Ticker: RVPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reviva Pharmaceuticals Holdings, Inc. filings document a Nasdaq-listed biopharmaceutical issuer developing drug candidates for CNS, inflammatory and cardiometabolic diseases. Its 8-K reports furnish operating and financial results, Regulation FD updates, and material-event disclosures tied to the brilaroxazine schizophrenia program, intellectual-property strategy, public offerings, and capital structure.
Proxy and other filings cover shareholder voting matters, director elections, auditor ratification, executive compensation, authorized share amendments, certificate amendments, security-holder rights, and Nasdaq listing-compliance notices. The filings also identify the company's common stock under symbol RVPH and describe common-stock, warrant and governance disclosures relevant to its public-company reporting.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) received an amended Schedule 13G filing showing that several Millennium-affiliated entities and Israel A. Englander collectively report beneficial ownership of Reviva common stock. The cover pages state that Integrated Core Strategies (US) LLC reports 3,254,631 shares, while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report 3,257,670 shares of common stock, representing 2.8% of the outstanding class as of the event date of December 31, 2025. The filers indicate they own 5% or less of the company’s common stock and certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Reviva.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) furnished an 8-K announcing it issued a press release with financial information and operating metrics for the fiscal quarter ended September 30, 2025, and discussed its business outlook.
The materials were furnished under Items 2.02 and 7.01 and are not deemed “filed” for liability purposes. The press release is included as Exhibit 99.1.
Reviva Pharmaceuticals (RVPH) filed its Q3 2025 10‑Q, reporting a narrower net loss and added capital from recent offerings. Net loss was $4.0 million for the quarter (vs. $8.4 million a year ago) and $16.5 million for the nine months (vs. $23.7 million). Operating expenses declined sharply as R&D fell to $2.1 million and G&A to $1.9 million in Q3.
Cash and cash equivalents were $13.2 million with total assets of $14.3 million and current liabilities of $9.7 million. Stockholders’ equity improved to $4.5 million. The company completed a June 2025 offering (20.0M shares with Series C/D warrants; gross $10.0M, net about $9.0M) and a September 2025 offering (27.0M shares with Series E/F warrants; gross $9.0M, net about $8.1M). It also sold 2.45M shares via its ATM for roughly $1.2M net.
The company disclosed substantial doubt about its ability to continue as a going concern. Subsequent to quarter‑end, warrant exercises in October–November 2025 added 18.7M shares for approximately $6.4M gross. Shares outstanding were 96,337,119 as of September 30, 2025, and 115,058,619 as of November 11, 2025.
Reviva Pharmaceuticals Holdings (RVPH) called its 2025 annual meeting for December 18, 2025 at 11:00 a.m. Pacific Time, to be held virtually. Stockholders will vote on electing five directors, ratifying Baker Tilly US, LLP as auditor for 2025, an advisory say‑on‑pay, and two capital-structure items.
The Board seeks approval to increase authorized common shares from 315,000,000 to 515,000,000 and to authorize a reverse stock split of issued common shares at a ratio between 1:2 and 1:20, at any time prior to December 31, 2026, at the Board’s discretion and without further stockholder approval. An adjournment proposal is included if additional solicitation is needed. The Board recommends voting “FOR” all proposals.
Holders of record as of October 21, 2025 may vote; 114,078,619 shares of common stock were outstanding on the record date. Voting can be completed online, by phone, by mail, or during the virtual meeting using a 16‑digit control number.
Reviva Pharmaceuticals Holdings (RVPH) filed a preliminary proxy for its virtual Annual Meeting on December 18, 2025. Stockholders will vote to elect five directors, ratify Baker Tilly US, LLP as auditor, approve an advisory say‑on‑pay, and consider two capital structure items: increasing authorized common stock from 315,000,000 to 515,000,000 and authorizing a reverse stock split at a ratio between 1:2 and 1:20, which the Board may implement at its discretion any time before December 31, 2026. An adjournment proposal is also included.
The Board recommends voting “FOR” all proposals. Only holders of record as of October 21, 2025 may vote; shares outstanding were 114,078,619 as of that date. Director elections use a plurality standard, while the auditor ratification, say‑on‑pay, authorized share increase, reverse split, and adjournment proposals require a majority of votes properly cast. The meeting will be held online at www.virtualshareholdermeeting.com/RVPH2025.
Reviva Pharmaceuticals Holdings (RVPH) reported that Nasdaq confirmed the company has regained compliance with the minimum Market Value of Listed Securities requirement. Nasdaq determined RVPH’s MVLS was $35 million or greater for 10 consecutive business days from September 30, 2025 to October 13, 2025, closing that matter.
The company remains out of compliance with Nasdaq’s $1.00 minimum bid price rule, with an initial 180‑day window to regain compliance until November 10, 2025. Reviva said it will continue monitoring its share price and may consider actions, including a potential reverse stock split, noting there is no assurance it will regain or maintain compliance.
683 Capital Management, LLC, 683 Capital Partners, LP and Ari Zweiman report beneficial ownership of 5,435,000 shares of Reviva Pharmaceuticals Holdings, Inc., representing approximately 5.36% of the company’s common stock on a fully-diluted basis as of September 29, 2025. The stake comprises 450,000 issued shares and 4,985,000 currently exercisable warrants, and the reporting persons note shared voting and dispositive power.
The filing states the position is not held to influence control of the issuer and lists reporting addresses in New York and Delaware organizational details.
Reviva Pharmaceuticals Holdings, Inc. amended its Bylaws on September 26, 2025 to lower the quorum for stockholder meetings from a majority of voting power to one-third (33 1/3%) of the voting power outstanding and entitled to vote, as present in person, by remote communication, or by proxy, except where a higher quorum is required by law or the certificate of incorporation or bylaws. The amendment was approved by the Board and the full text is filed as Exhibit 3.1.
Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.
Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.
Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.
Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.